eISSN: 2353-9461
ISSN: 0860-7796
BioTechnologia
Current issue Archive About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Newsletter
Enter your email:
 
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees

Journal integrated with

integrated with publons
3/2024
vol. 105
 
Share:
Send email
Share:
abstract:
RESEARCH PAPERS

Induction of an immune response by a nonreplicating adenoviruses-based formulation versus a commercial pseudo-SARS-CoV-2 vaccine

Joanna Baran
1
,
Łukasz Kuryk
2
,
Mariangela Garofalo
3
,
Katarzyna Pancer
2
,
Magdalena Wieczorek
2
,
Michalina Kazek
1
,
Monika Staniszewska
1

  1. Centre for Advanced Materials and Technologies, Warsaw University of Technology, Warszawa, Poland
  2. National Institute of Public Health National Institute of Hygiene (NIH) – National Institute of Research, Warszawa, Poland
  3. Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy
BioTechnologia vol. 105(3) ∙ pp. 263–272 ∙ 2024
DOI: https://doi.org/10.5114/bta.2024.141805
Online publish date: 2024/09/30
View full text Get citation
 
PlumX metrics:
Screening for effective vaccines requires broad studies on their immunogenicity in vitro and ex vivo. We used a PBMC-based system to assess changes in CD4+ T cells, CD8+ T cells, and CD19+ B cells upon stimulation with different combinations of antigens and adjuvants. We studied the activation mechanism using flow cytometry and two different adenoviral adjuvants characterized by the presence or absence of costimulatory ligands for the ICOS and CD40 receptors. Our studies identified the cellular targets and molecular mechanisms driving ongoing switched-antibody diversification. Class-switched memory B cells were the main precursor cells (95.03%±0.38 vs. mock 82.33%±0.45, P < 0.05) after treatment with the immunogenic formula: adenovirus armed (MIX1) or not (MIX2) with the ICOS and CD40 ligand, the recombinant receptor binding domain (rRBD), and Lentifect™ SARS-CoV-2 spike-pseudotyped lentivirus (GeneCopoeia, USA). Bcell class-switching towards the IgG+IgM+-positive phenotypes was noted (∼50-fold increase vs. mock, P < 0.05). A significant increase was observed in the CD8+TEM population of the MIX1 (∼2-fold, P < 0.05) and MIX2 (∼4.7-fold, P < 0.05) treated samples. CD8+TEMRA increased when PBMCs were treated with MIX2 (9.63%±0.90, P < 0.05) vs. mock (2.63%±1.96). Class-switched memory B cells were the dominant antigen-specific cells in primary reactions. We indicated a correlation between the protection offered by vaccine regimens and their ability to induce high frequencies of multifunctional T cells.
keywords:

immune response, adenoviruses, vaccines, SARS-CoV-2, CD cells


Stosujemy się do standardu HONcode dla wiarygodnej informacji zdrowotnej This site complies with the HONcode standard for trustworthy health information: verify here
Hosted by Termedia sp. z o.o.